1Dual characters of proteasomes and drug designGUO Zong-ru2433-24392Development status and problems of biomedical industrial parks in ChinaXU Kai, SUN Li-hua2440-24463Study on drug characteristics of NCCN and CSCO clinical practice guidelines for high-prevalence tumors in ChinaZHANG Song-lin, AI Dan-dan, ZHANG Ran, CHANG Feng2447-24524Cluster analysis of the current status and research hotspots of non-Hodgkin's lymphoma based on PubMed databaseZHANG Ya-ni, WU Fen, WANG Shu-min, LIU Chao, YANG Hao, ZHOU Jian-ping, ZHANG Li-tao2453-24605Economic operation of Chinese pharmaceutical industry in the first quarter of 2019GUO Wen, ZHONG Yi-ming, ZHOU Bin2461-24676Considerations on the design and implementation of chemical drugs stress testingGUO Di-liang2468-24727Common problems analyses in the quality control and in vitro evaluation on consistency evaluation of oral solid dosage formsSHI Jing, XU Zhen-yu2473-24778Determination of the contents of N-nitrosodimethylamine in valsartan by GC-MSWU Zhao-wei, DU Kai, WANG Lin, ZHENG Jie, HU Qin, ZHANG Zhe, WU Bin2478-24819The proficiency testing for determination of osmolality of recombinant protein injectionQIN Xi, DING You-xue, ZHANG He-zhan, ZHAO Meng, LIU Lan, SHI Xin-chang, RAO Chun-ming2482-248510Progress in clinical research on cabozantinib in the treatment of malignant tumorsWANG Long, ZHANG Li, WANG Juan, GE Chao-liang2486-249111Advances in the targeted inhibitors of ovarian cancerWANG Zhi-wen, TANG Hai-fei, ZHENG Xue-song, ZHANG Ting2492-249712Research progress on dissolution behavior of solid preparations of traditional Chinese medicineZHANG Qiang, LI Pian, SUN Yang-en, JIN Yu-cui, LI Zheng, QU Hai-bin, LI Wen-long2498-250113Review of the features and clinical application of a novel broad-spectrum cephalosporin: ceftobiprole medocarilRUAN Gen-jie, LIU Mei-qiong, MA Ya-kun, ZHENG Bo2502-250714Perspectives on the performing of investigators' responsibilities from drug clinical trial data inspectionGAO Rong, L(U) Shu-chao, LI Xiu-li, LEI Ming-wu, QIAN Xue2508-251215Perspectives on the implementation of ethics committee's responsibilities from drug clinical trial data inspectionGAO Rong, TANG Jing, FANG Xiang, LEI Ming-wu, ZHANG Qiong-guang2513-251716Perspectives on the implementation of responsibilities of drug clinical trial institutions from drug clinical trial data inspectionGAO Rong, NING Jing, WANG An-na, FANG Xiang, ZHANG Rong2518-252317The status and promotion strategy of subjects education in clinical trials of new drugs in ChinaLI Shu-ting, HAO Peng, MAO Dong-lei, HE Wen-jun, DAI Jia-ling, YANG Shuang, CAO Xiao-chun, CHANG Jian-qing2524-252818Analysis of problems related to informed consent in investigator-initiated clinical researchesLI Hui-juan, SONG Mei, WANG Mei-rong, WANG Yan, WU Yang-feng2529-253219Effect of paliperidone combined with social cognitive training on cognitive functionLI Yi-chen, MA Jun, XIE Jun, SUN Ke2533-253620Effects of nobiletin on high glucose-induced inflammatory cytokines and oxidative stress in rat mesangial cellsLI Hui-ying, ZHAO Xiao-li, WANG Li, QIU Qiang, WANG Zhen2537-2542 